Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:5744
Name ovary serous adenocarcinoma
Definition An ovary adenocarcinoma that derives_from the lining of a cavity that produces a serum-like fluid (a serous cavity).
Source DiseaseOntology.org
Alt Ids DOID:5745
Path disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer ovarian cancer ovary epithelial cancer malignant ovarian surface epithelial-stromal neoplasm ovarian carcinoma ovary adenocarcinoma ovary serous adenocarcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
RAD51B wild-type Cediranib + Olaparib ovary serous adenocarcinoma predicted - sensitive detail...
RAD51B mutant Cediranib + Olaparib ovary serous adenocarcinoma predicted - sensitive detail...
BRAF V600E Vemurafenib ovary serous adenocarcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01853306 Phase I Veliparib A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors Completed 0
NCT02068794 Phase Ib/II MV-NIS MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Active, not recruiting USA 0
NCT02282020 Phase III Topotecan Paclitaxel Pegylated liposomal doxorubicin Gemcitabine Olaparib Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments (SOLO3) Completed USA | POL | ITA | ISR | HUN | ESP | CZE | CAN | BRA | BEL | ARG 2
NCT02316834 Phase I Talazoparib POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer Completed USA 0
NCT02345265 Phase II Cediranib + Olaparib Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer Active, not recruiting USA 0
NCT02354586 Phase II Niraparib A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens Completed USA | CAN 0
NCT02584478 Phase Ib/II Anlotinib + Carboplatin + Paclitaxel Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) Active, not recruiting USA | ITA | GBR | ESP 2
NCT02889900 Phase II Cediranib + Olaparib Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO) Completed USA 0
NCT03277209 Phase I Plerixafor To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas Terminated USA | GBR 0
NCT03507452 Phase I BAY2287411 First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin Completed USA | SWE | NLD | GBR | FIN 0
NCT03586661 Phase I Copanlisib + Niraparib Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting USA 0
NCT03608618 Phase I MCY-M11 Cyclophosphamide Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma Terminated USA 0
NCT03733990 Phase Ib/II FP-1305 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) Completed USA | NLD | GBR | FRA | FIN | ESP 0
NCT03737643 Phase III Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Durvalumab + Paclitaxel Bevacizumab + Durvalumab + Olaparib Olaparib Bevacizumab + Durvalumab Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. (DUO-O) Active, not recruiting USA | TUR | ROU | POL | ITA | HUN | FRA | FIN | ESP | DNK | DEU | CAN | BRA | BGR | BEL | AUT 4
NCT03839524 Phase I TG4050 A Trial Evaluating TG4050 in Ovarian Carcinoma. Active, not recruiting USA | FRA 0
NCT03907852 Phase Ib/II Gavocabtagene autoleucel + Ipilimumab + Nivolumab Gavocabtagene autoleucel + Nivolumab Gavocabtagene autoleucel Cyclophosphamide + Fludarabine Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer Active, not recruiting USA | CAN 0
NCT04149145 Phase I Niraparib + VX-803 Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer Withdrawn 0
NCT04498117 Phase III Carboplatin + Oregovomab + Paclitaxel Carboplatin + Paclitaxel Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (FLORA-5) Active, not recruiting USA | ITA | HUN | ESP | CZE | CAN | BRA | BEL | ARG 5
NCT04598321 Phase I Talazoparib BrUOG 390: Neoadjuvant Treatment With Talazoparib Terminated USA 0
NCT04706962 Phase I TH1902 TH1902 in Patients With Advanced Solid Tumors Recruiting USA | CAN 0
NCT04729608 Phase III AVB-S6-500 + Paclitaxel Paclitaxel Study of AVB-S6-500 in Combination With Paclitaxel vs Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer Terminated USA | POL | ITA | GBR | FRA | ESP | CZE | CAN | BEL 2
NCT04884360 Phase III Olaparib D9319C00001- 1L OC Mono Global RCT (MONO-OLA1) Active, not recruiting TUR 9
NCT05032040 Phase II XmAb20717 A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies Recruiting USA 0
NCT05074472 Phase Ib/II ZB131 A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors Completed USA 0
NCT05194072 Phase I SGN-B7H4V A Study of SGN-B7H4V in Advanced Solid Tumors Recruiting USA | ITA | GBR | ESP | DEU | CAN 0
NCT05397093 Phase I ITIL-306 ITIL-306 in Advanced Solid Tumors Active, not recruiting USA 0
NCT05451849 Phase Ib/II Cyclophosphamide + Fludarabine TC-510 A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer Active, not recruiting USA 0
NCT05538624 Phase Ib/II AVB-001 A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary Terminated USA 0
NCT05547321 Phase I OMTX705 + Pembrolizumab OMTX705 Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors. Recruiting USA | ESP 0